Pear Therapeutics Inc. (PEARQ)

OTCMKTS: PEARQ · Delayed Price · USD
0.00
0.00 (0.00%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines in the United States.

Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia.

The company is also developing a pipeline of product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastroenterology, cardiology, and oncology.

Pear Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. On April 7, 2023, Pear Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Pear Therapeutics Inc.
Pear Therapeutics logo
Country MA
Founded 2013
Industry Health Information Services
Sector Healthcare
Employees 200

Contact Details

Address:
200 State Street, 13th Floor
Boston, Massachusetts 02109
United States
Phone 6469322774

Stock Details

Ticker Symbol PEARQ
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001835567
Employer ID 85-4103092
SIC Code 8000

Key Executives

Name Position
Dr. Corey M. McCann M.D., Ph.D. Founder and Director
Ilya Gluhovsky Ph.D. Vice President and Chief Technology Officer
Meara Murphy Senior Director of Corporate Communications
Chris Valosky M.B.A. Vice President of Sales, Commercial Partnership and Marketing
Martha Carruthers M.B.A. Vice President of Corporate Development
Dr. Yuri Maricich M.B.A., M.D. Chief Medical Officer and Head of Development
Erin K. Brenner Chief Product Development Officer

Latest SEC Filings

Date Type Title
May 2, 2023 25-NSE Filing
Apr 28, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Apr 12, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Apr 10, 2023 8-K Current Report
Apr 7, 2023 8-K Current Report
Mar 31, 2023 10-K Annual Report
Mar 17, 2023 8-K Current Report
Feb 24, 2023 8-K Current Report
Feb 14, 2023 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2023 S-8 Securities to be offered to employees in employee benefit plans